Efficacy of intermittent topical 5-fluorouracil 5% and oral nicotinamide in the skin field cancerization: a randomized clinical trial
An. bras. dermatol; 96 (6), 2021
Results: 6
Acantholytic pityriasis rubra pilaris associated with topical use of imiquimod 5%: case report and literature review
An. bras. dermatol; 95 (1), 2020
Abstract Topical use of immune response modifiers, such as imiquimod, has increased in dermatology. Although its topical use is well tolerated, it may be associated with exacerbations of generalized cutaneous inflammatory diseases, possibly through the systemic circulation of pro-inflammatory cytokines. ...
Corticoesteroides/uso terapéutico, Antineoplásicos/efectos adversos, Biopsia, Fármacos Dermatológicos/uso terapéutico, Imiquimod/efectos adversos, Queratosis Actínica/tratamiento farmacológico, Metotrexato/uso terapéutico, Persona de Mediana Edad, Pitiriasis Rubra Pilaris/inducido químicamente, Pitiriasis Rubra Pilaris/tratamiento farmacológico, Pitiriasis Rubra Pilaris/patología, Resultado del Tratamiento
Treatment of actinic keratoses and cancerization field of the face and scalp with 0 015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives
An. bras. dermatol; 94 (3), 2019
Abstract: Background: Actinic keratosis (AK) represents a risk of progression to squamous cell carcinoma. Ingenol mebutate gel is a novel therapeutic option for field-directed treatment. Objectives: To evaluate the safety, tolerability and patients' perspectives, related to the therapeutic success of m...
Administración Cutánea, Brasil, Fármacos Dermatológicos/uso terapéutico, Diterpenos/uso terapéutico, Dermatosis Facial/tratamiento farmacológico, Geles/uso terapéutico, Queratosis Actínica/tratamiento farmacológico, Estudios Retrospectivos, Dermatosis del Cuero Cabelludo/tratamiento farmacológico, Encuestas y Cuestionarios, Resultado del Tratamiento
Queilitis actínica: Reporte de tres casos y revisión de literatura
Odovtos (En línea); 20 (3), 2018
RESUMEN La queilitis actínica (QA) es un desorden potencialmente maligno del labio inducido por la exposición crónica a la luz ultravioleta, que afecta principalmente al bermellón del labio inferior de personas adultas y de piel clara. Si no es tratada en forma oportuna puede transformarse en un carc...
Ingenol mebutate in the treatment of actinic keratoses: clearance rate and adverse effects
An. bras. dermatol; 93 (4), 2018
Abstract: Background: Actinic keratoses are benign intraepithelial skin neoplasms that develop in photoexposed areas and can progress to invasive carcinoma. They are seen frequently in dermatological practice, occurring in 5.1% of consultations. Ingenol mebutate (IM) was recently approved in Brazil as a...
Daylight photodynamic therapy - Experience and safety in treatment of actinic keratoses of the face and scalp in low latitude and high brightness region
An. bras. dermatol; 92 (1), 2017
ABSTRACT Daylight photodynamic therapy has been used in countries with high latitudes during the summer for actinic keratoses treatment with reports of similar efficacy to conventional photodynamic therapy. We evaluate its safety in 20 patients in the city of Fortaleza, a local with low latitude and high...
Dermatosis Facial/tratamiento farmacológico, Queratosis Actínica/tratamiento farmacológico, Fotoquimioterapia/métodos, Dermatosis del Cuero Cabelludo/tratamiento farmacológico, Luz Solar, Ácido Aminolevulínico/análogos & derivados, Ácido Aminolevulínico/uso terapéutico, Relación Dosis-Respuesta en la Radiación, Fármacos Fotosensibilizantes/uso terapéutico, Factores de Tiempo, Resultado del Tratamiento